Clinical trial
Study In Patients With Insulin Resistance
NCT00197132 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00197132 |
|---|---|
| Title | Study In Patients With Insulin Resistance |
| Official title | A Single-centre, Randomised, Double-blind, Placebo Controlled, Two 12 Week Period, Cross-over Phase III Study to Investigate the Effect of Rosiglitazone 4mg bd on the Vasodilator Response to Hyperinsulinaemia in Obese Insulin Resistant Subjects. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Insulin Resistance |
| Intervention type | Drug |
| Interventions | Avandia |
| Enrollment | 18 |
| Start date | Oct 1, 2002 |
| Primary completion | Aug 1, 2003 |
| Completion | Aug 1, 2003 |
| First posted | Sep 20, 2005 |
| Last update posted | Dec 5, 2016 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: